antagonist

(redirected from Aldosterone antagonist)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Aldosterone antagonist: potassium sparing diuretics
References in periodicals archive ?
The current findings have the potential to greatly expand the use of aldosterone antagonists, which are now utilized by fewer than two-thirds of patients with heart failure in the United States with a current indication.
Sixty-nine of the patients were treated with an aldosterone antagonist as part of their multidrug, blood pressure-lowering regimen.
Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Aldosterone antagonists (AA).
Currently, two aldosterone antagonists are available commercially.
Key Words: heart failure, left ventricular dysfunction, angiotensin-converting enzyme inhibitors, beta blockers, aldosterone antagonists, angiotensin-receptor blockers, digoxin
Preoperatively the patient should be placed on spironolactone or eplerenone; these aldosterone antagonists block the effects of aldosterone on the kidney, with resultant normalization of hypertension and hypokalemia.
The latest heart failure guidelines from the American College of Cardiology/ American Heart Association place a new emphasis on aldosterone antagonists as a central aspect of the management of symptomatic or previously symptomatic heart failure with reduced ejection fraction--while underscoring important caveats to their use.
Joe is taking an angiotensin-converting enzyme (ACE) inhibitor, a beta-blocker, an aldosterone antagonist, a loop diuretic, a nitrate, and digoxin, and he has an implantable cardioverter defibrillator (ICD).
Patients were already treated with an ACEI, ARB and aldosterone antagonist.
Objective: This study investigates whether the combination of thiazides with an aldosterone antagonist can decrease their negative effects on the fibrinolytic activity.
Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalA[degrees]ization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Health.
Yet the aldosterone antagonist actually showed a significant positive result for the composite endpoint in North and South American participants.